Clinical Trial Update: Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated pembrolizumab plus lenvatinib as first-line therapy for advanced/non-clear cell renal cell carcinoma. Results have been posted after t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-12-03